Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells

Journal of Experimental Medicine

Volumn 208, Issue 10, 2011, Pages 1977-1988

  Xu, Dan ^a   Liu, Xia ^a   Yu, Wen Mei ^a   Meyerson, Howard J ^a   Guo, Caiying ^b   Gerson, Stanton L ^a   Qu, Cheng Kui ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; CANCER STEM CELL; CELL LINEAGE; CENTROSOME; CONTROLLED STUDY; EMBRYO; GENE; GENE AMPLIFICATION; GENE MUTATION; GENOMIC INSTABILITY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETHALITY; MALIGNANT TRANSFORMATION; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PTPN11 GENE; T CELL LEUKEMIA; TISSUE SPECIFICITY;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CENTROSOME; CHROMOSOMAL INSTABILITY; EMBRYO, MAMMALIAN; GENE KNOCK-IN TECHNIQUES; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 80555139701     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20110450     Document Type: Article

References (63)

1. Aoki, Y., T. Niihori, Y. Narumi, S. Kure, and Y. Matsubara. 2008. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum. Mutat. 29:992-1006. http://dx.doi.org/10.1002/humu.20748
2. Araki, T., M.G. Mohi, F.A. Ismat, R.T. Bronson, I.R. Williams, J.L. Kutok, W. Yang, L.I. Pao, D.G. Gilliland, J.A. Epstein, and B.G. Neel. 2004. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10:849-857. http://dx.doi.org/10.1038/nm1084
3. Barford, D., and B.G. Neel. 1998. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure. 6:249-254. http://dx.doi.org/10.1016/S0969-2126(98)00027-6
4. Bennett, A.M., T.L. Tang, S. Sugimoto, C.T. Walsh, and B.G. Neel. 1994. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc. Natl. Acad. Sci. USA. 91:7335-7339. http://dx.doi.org/10.1073/pnas.91.15.7335
5. Bentires-Alj, M., J.G. Paez, F.S. David, H. Keilhack, B. Halmos, K. Naoki, J.M. Maris, A. Richardson, A. Bardelli, D.J. Sugarbaker, et al. 2004. Activating mutations of the noonan syndrome-associated SHP2/ PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64:8816-8820. http://dx.doi.org/10.1158/0008-5472.CAN-04-1923
6. Birnbaum, R.A., A. O'Marcaigh, Z. Wardak, Y.Y. Zhang, G. Dranoff, T. Jacks, D.W. Clapp, and K.M. Shannon. 2000. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol. Cell. 5:189-195. http://dx.doi.org/10.1016/S1097-2765(00)80415-3
7. Chan, R.J., M.B. Leedy, V. Munugalavadla, C.S. Voorhorst, Y. Li, M. Yu, and R. Kapur. 2005. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colonystimulating factor. Blood. 105:3737-3742. http://dx.doi.org/10.1182/blood-2004-10-4002
8. Chan, G., D. Kalaitzidis, T. Usenko, J.L. Kutok, W. Yang, M.G. Mohi, and B.G. Neel. 2009. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 113:4414-4424. http://dx.doi.org/10.1182/blood-2008-10-182626
9. Chan, G., L.S. Cheung, W. Yang, M. Milyavsky, A.D. Sanders, S. Gu, W.X. Hong, A.X. Liu, X. Wang, M. Barbara, et al. 2011. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 117:4253-4261. http://dx.doi.org/10.1182/blood-2010-11-319517
10. Cheng, T., N. Rodrigues, H. Shen, Y. Yang, D. Dombkowski, M. Sykes, and D.T. Scadden. 2000. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 287:1804-1808. http://dx.doi.org/10.1126/science.287.5459.1804
11. Corson, L.B., Y. Yamanaka, K.M. Lai, and J. Rossant. 2003. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development. 130:4527-4537. http://dx.doi.org/10.1242/dev.00669
12. Cozzio, A., E. Passegué, P.M. Ayton, H. Karsunky, M.L. Cleary, and I.L. Weissman. 2003. Similar MLL-associated leukemias arising from selfrenewing stem cells and short-lived myeloid progenitors. Genes Dev. 17:3029-3035. http://dx.doi.org/10.1101/gad.1143403
13. Draviam, V.M., S. Xie, and P.K. Sorger. 2004. Chromosome segregation and genomic stability. Curr. Opin. Genet. Dev. 14:120-125. http://dx.doi.org/10.1016/j.gde.2004.02.007
14. Eck, M.J., S. Pluskey, T. Trüb, S.C. Harrison, and S.E. Shoelson. 1996. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature. 379:277-280. http://dx.doi.org/10.1038/379277a0
15. Fleming, H.E., V. Janzen, C. Lo Celso, J. Guo, K.M. Leahy, H.M. Kronenberg, and D.T. Scadden. 2008. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve selfrenewal in vivo. Cell Stem Cell. 2:274-283. http://dx.doi.org/10.1016/j.stem.2008.01.003
16. Fragale, A., M. Tartaglia, J. Wu, and B.D. Gelb. 2004. Noonan syndromeassociated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23:267-277. http://dx.doi.org/10.1002/humu.20005
17. Guo, W., J.L. Lasky, C.J. Chang, S. Mosessian, X. Lewis, Y. Xiao, J.E. Yeh, J.Y. Chen, M.L. Iruela-Arispe, M. Varella-Garcia, and H. Wu. 2008. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 453:529-533. http://dx.doi.org/10.1038/nature06933
18. Hof, P., S. Pluskey, S. Dhe-Paganon, M.J. Eck, and S.E. Shoelson. 1998. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 92:441-450. http://dx.doi.org/10.1016/S0092-8674(00)80938-1
19. Jude, C.D., L. Climer, D. Xu, E. Artinger, J.K. Fisher, and P. Ernst. 2007. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 1:324-337. http://dx.doi.org/10.1016/j.stem.2007.05.019
20. Kalaitzidis, D., and B.G. Neel. 2008. Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS ONE. 3:e3776. http://dx.doi.org/10.1371/journal.pone.0003776
21. Kastan, M.B., and J. Bartek. 2004. Cell-cycle checkpoints and cancer. Nature. 432:316-323. http://dx.doi.org/10.1038/nature03097
22. Keilhack, H., F.S. David, M. McGregor, L.C. Cantley, and B.G. Neel. 2005. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 280:30984-30993. http://dx.doi.org/10.1074/jbc.M504699200
23. Kiel, M.J., O.H. Yilmaz, T. Iwashita, O.H. Yilmaz, C. Terhorst, and S.J. Morrison. 2005. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 121:1109-1121. http://dx.doi.org/10.1016/j.cell.2005.05.026
24. Kirstetter, P., M.B. Schuster, O. Bereshchenko, S. Moore, H. Dvinge, E. Kurz, K. Theilgaard-Mönch, R. Månsson, T.A. Pedersen, T. Pabst, et al. 2008. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemiainitiating cells. Cancer Cell. 13:299-310. http://dx.doi.org/10.1016/j.ccr.2008.02.008
25. Kontaridis, M.I., K.D. Swanson, F.S. David, D. Barford, and B.G. Neel. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281:6785-6792. http://dx.doi.org/10.1074/jbc.M513068200
26. Kratz, C.P., C.M. Niemeyer, R.P. Castleberry, M. Cetin, E. Bergsträsser, P.D. Emanuel, H. Hasle, G. Kardos, C. Klein, S. Kojima, et al. 2005. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood. 106:2183-2185. http://dx.doi.org/10.1182/blood-2005-02-0531
27. Kühn, R., F. Schwenk, M. Aguet, and K. Rajewsky. 1995. Inducible gene targeting in mice. Science. 269:1427-1429. http://dx.doi.org/10.1126/science.7660125
28. Li, W., R. Nishimura, A. Kashishian, A.G. Batzer, W.J. Kim, J.A. Cooper, and J. Schlessinger. 1994. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol. Cell. Biol. 14:509-517.
29. Liu, P., N.A. Jenkins, and N.G. Copeland. 2003. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13:476-484. http://dx.doi.org/10.1101/gr.749203
30. Loh, M.L., M.G. Reynolds, S. Vattikuti, R.B. Gerbing, T.A. Alonzo, E. Carlson, J.W. Cheng, C.M. Lee, B.J. Lange, and S. Meshinchi Children's Cancer Group. 2004a. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia. 18:1831-1834. http://dx.doi.org/10.1038/sj.leu.2403492
31. Loh, M.L., S. Vattikuti, S. Schubbert, M.G. Reynolds, E. Carlson, K.H. Lieuw, J.W. Cheng, C.M. Lee, D. Stokoe, J.M. Bonifas, et al. 2004b. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 103:2325-2331. http://dx.doi.org/10.1182/blood-2003-09-3287
32. Mohi, M.G., I.R. Williams, C.R. Dearolf, G. Chan, J.L. Kutok, S. Cohen, K. Morgan, C. Boulton, H. Shigematsu, H. Keilhack, et al. 2005. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 7:179- 191. http://dx.doi.org/10.1016/j.ccr.2005.01.010
33. Neel, B.G., H. Gu, and L. Pao. 2003. The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28:284-293. http://dx.doi.org/10.1016/S0968-0004(03)00091-4
34. Pawson, T. 2004. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell. 116:191-203. http://dx.doi.org/10.1016/S0092-8674(03)01077-8
35. Qu, C.K., Z.Q. Shi, R. Shen, F.Y. Tsai, S.H. Orkin, and G.S. Feng. 1997. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol. Cell. Biol. 17:5499-5507.
36. Qu, C.K., W.M. Yu, B. Azzarelli, S. Cooper, H.E. Broxmeyer, and G.S. Feng. 1998. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol. Cell. Biol. 18:6075-6082.
37. Qu, C.K., W.M. Yu, B. Azzarelli, and G.S. Feng. 1999. Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc. Natl. Acad. Sci. USA. 96:8528- 8533. http://dx.doi.org/10.1073/pnas.96.15.8528
38. Qu, C.K., S. Nguyen, J. Chen, and G.S. Feng. 2001. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood. 97:911-914. http://dx.doi.org/10.1182/blood.V97.4.911
39. Rosenbauer, F., K. Wagner, J.L. Kutok, H. Iwasaki, M.M. Le Beau, Y. Okuno, K. Akashi, S. Fiering, and D.G. Tenen. 2004. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat. Genet. 36:624-630. http://dx.doi.org/10.1038/ng1361
40. Ruchaud, S., M. Carmena, and W.C. Earnshaw. 2007. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 8:798-812. http://dx.doi.org/10.1038/nrm2257
41. Saxton, T.M., M. Henkemeyer, S. Gasca, R. Shen, D.J. Rossi, F. Shalaby, G.S. Feng, and T. Pawson. 1997. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16:2352-2364. http://dx.doi.org/10.1093/emboj/16.9.2352
42. Schindler, J.W., D. Van Buren, A. Foudi, O. Krejci, J. Qin, S.H. Orkin, and H. Hock. 2009. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell. 5:43-53. http://dx.doi.org/10.1016/j.stem.2009.04.019
43. Schubbert, S., K. Lieuw, S.L. Rowe, C.M. Lee, X. Li, M.L. Loh, D.W. Clapp, and K.M. Shannon. 2005. Functional analysis of leukemiaassociated PTPN11 mutations in primary hematopoietic cells. Blood. 106:311-317. http://dx.doi.org/10.1182/blood-2004-11-4207
44. Smith, L.J., J.E. Curtis, H.A. Messner, J.S. Senn, H. Furthmayr, and E.A. McCulloch. 1983. Lineage infidelity in acute leukemia. Blood. 61:1138-1145.
45. So, C.W., H. Karsunky, E. Passegué, A. Cozzio, I.L. Weissman, and M.L. Cleary. 2003. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell. 3:161-171. http://dx.doi.org/10.1016/S1535-6108(03)00019-9
46. Songyang, Z., and L.C. Cantley. 2004. ZIP codes for delivering SH2 domains. Cell. 116(2, Suppl):S41-S43: 2: S48. http://dx.doi.org/10.1016/S0092-8674(04)00041-8
47. Tartaglia, M., E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, H. Kremer, I. van der Burgt, A.H. Crosby, A. Ion, S. Jeffery, et al. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29:465-468. http://dx.doi.org/10.1038/ng772
48. Tartaglia, M., C.M. Niemeyer, A. Fragale, X. Song, J. Buechner, A. Jung, K. Hählen, H. Hasle, J.D. Licht, and B.D. Gelb. 2003. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34:148-150. http://dx.doi.org/10.1038/ng1156
49. Tartaglia, M., S. Martinelli, G. Cazzaniga, V. Cordeddu, I. Iavarone, M. Spinelli, C. Palmi, C. Carta, A. Pession, M. Aricò, et al. 2004. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 104:307-313. http://dx.doi.org/10.1182/blood-2003-11-3876
50. Tartaglia, M., S. Martinelli, L. Stella, G. Bocchinfuso, E. Flex, V. Cordeddu, G. Zampino, I. Burgt, A. Palleschi, T.C. Petrucci, et al. 2006. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78:279-290. http://dx.doi.org/10.1086/499925
51. Tonks, N.K. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7:833-846. http://dx.doi.org/10.1038/nrm2039
52. Tothova, Z., R. Kollipara, B.J. Huntly, B.H. Lee, D.H. Castrillon, D.E. Cullen, E.P. McDowell, S. Lazo-Kallanian, I.R. Williams, C. Sears, et al. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 128:325-339. http://dx.doi.org/10.1016/j.cell.2007.01.003
53. Waksman, G., and J. Kuriyan. 2004. Structure and specificity of the SH2 domain. Cell. 116(2, Suppl):S45-S48: 3: S48. http://dx.doi.org/10.1016/S0092-8674(04)00043-1
54. Xu, D., and C.K. Qu. 2008. Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13:4925-4932. http://dx.doi.org/10.2741/3051
55. Xu, D., S. Wang, W.M. Yu, G. Chan, T. Araki, K.D. Bunting, B.G. Neel, and C.K. Qu. 2010. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood. 116:3611-3621. http://dx.doi.org/10.1182/blood-2010-01-265652
56. Yang, W., L.D. Klaman, B. Chen, T. Araki, H. Harada, S.M. Thomas, E.L. George, and B.G. Neel. 2006. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev. Cell. 10:317-327. http://dx.doi.org/10.1016/j.devcel.2006.01.002
57. Yilmaz, O.H., R. Valdez, B.K. Theisen, W. Guo, D.O. Ferguson, H. Wu, and S.J. Morrison. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 441:475-482. http://dx.doi.org/10.1038/nature04703
58. Yu, W.M., T.S. Hawley, R.G. Hawley, and C.K. Qu. 2003. Catalyticdependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene. 22:5995-6004. http://dx.doi.org/10.1038/sj.onc.1206846
59. Yu, W.M., H. Daino, J. Chen, K.D. Bunting, and C.K. Qu. 2006. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. J. Biol. Chem. 281:5426-5434. http://dx.doi.org/10.1074/jbc.M507622200
60. Zhang, Y.Y., T.A. Vik, J.W. Ryder, E.F. Srour, T. Jacks, K. Shannon, and D.W. Clapp. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med. 187:1893-1902. http://dx.doi.org/10.1084/jem.187.11.1893
61. Zhang, J., J.C. Grindley, T. Yin, S. Jayasinghe, X.C. He, J.T. Ross, J.S. Haug, D. Rupp, K.S. Porter-Westpfahl, L.M. Wiedemann, et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 441:518-522. http://dx.doi.org/10.1038/nature04747
62. Zhao, R., X. Fu, L. Teng, Q. Li, and Z.J. Zhao. 2003. Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains. J. Biol. Chem. 278:42893-42898. http://dx.doi.org/10.1074/jbc.M306136200
63. Zhu, H.H., K. Ji, N. Alderson, Z. He, S. Li, W. Liu, D.E. Zhang, L. Li, and G.S. Feng. 2011. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood. 117:5350-5361. http://dx.doi.org/10.1182/blood-2011-01-333476